Helmholtz Gemeinschaft


CEBPA mutations in AML: site matters

Item Type:Editorial
Title:CEBPA mutations in AML: site matters
Creators Name:Bullinger, L.
Abstract:In this issue of Blood, based on a retrospective analysis of 4708 acute myeloid leukemia (AML) cases, Taube et al evaluate the impact of CCAAT/enhancer binding protein a (CEBPA) mutations and show that it is especially in-frame mutations affecting the basic leucine zipper region (bZIP) of CEPBA that confer a favorable outcome, irrespective of their occurrence as biallelic (CEBPAbi) or single mutation (CEBPAsm). Compared with transactivation domain (TAD) mutations, this study strongly supports a previously undefined role of CEBPA bZIP mutations, which is reflected in a distinct disease biology including younger age, higher white blood cell counts, the presence of GATA2 mutations, and high complete remission rates and long median event-free and overall survival.
Keywords:Acute Myeloid Leukemia, CCAAT-Enhancer-Binding Proteins, Mutation
Publisher:American Society of Hematology
Page Range:6-7
Date:6 January 2022
Official Publication:https://doi.org/10.1182/blood.2021013557
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library